Document is current
Any future updates will be listed below
-
Authors
Bebber, Christina M. http://orcid.org/0000-0002-7841-7493
Thomas, Emily S. http://orcid.org/0000-0002-4563-8695
Stroh, Jenny
Chen, Zhiyi
Androulidaki, Ariadne
Schmitt, Anna
Höhne, Michaela N.
Stüker, Lukas
de Pádua Alves, Cleidson
Khonsari, Armin
Dammert, Marcel A.
Parmaksiz, Fatma
Tumbrink, Hannah L.
Beleggia, Filippo http://orcid.org/0000-0003-0234-7094
Sos, Martin L. http://orcid.org/0000-0002-2868-100X
Riemer, Jan
George, Julie http://orcid.org/0000-0002-4272-3683
Brodesser, Susanne
Thomas, Roman K.
Reinhardt, H. Christian
von Karstedt, Silvia http://orcid.org/0000-0002-7816-5919
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (701125509)
Deutsche Forschungsgemeinschaft (SFB1399, SFB1403, 390661388)
- License Information
-
More Information
Article History
Received: 3 July 2020
Accepted: 9 March 2021
First Online: 6 April 2021
Change Date: 23 April 2021
Change Type: Update
Change Details: In the original version of this Article, the given and family names of author H. Christian Reinhardt were incorrectly tagged in the XML, leading to incorrect indexing. This error has now been corrected in the XML of the paper. The PDF and HTML versions displayed the name correctly at the time of publication.
Competing interests
: H.C.R. received consulting fees from Abbvie, AstraZeneca, Vertex and Merck and research funding from Gilead. R.K.T. is a co-founder of and was a consultant for NEO New Oncology, now part of Siemens Healthcare. R.K.T. and M.L.S. are co-founders of and consultants for PearlRiver Bio GmbH and M.L.S. receives funding from PearlRiver Bio GmbH. H.L.T. is a consultant for PearlRiver Bio GmbH. R.K.T. is a co-founder and consultant of Epiphanes Inc. R.K.T. is a stockholder of Roche, AstraZeneca, GSK, Merck, Qiagen, Novartis, Bayer and Johnson & Johnson. All other authors declare no competing interests.
